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Schizophrenia is a debilitating psychiatric condition often associated with poor quality of life 
and decreased life expectancy. Lack of progress in improving treatment outcomes has been 
attributed to limited knowledge of the underlying biology, although large-scale genomic 
studies have begun to provide such insight. We report the largest single cohort genome-wide 
association study of schizophrenia (11,260 cases and 24,542 controls) and through meta-
analysis with existing data we identify 50 novel GWAS loci. Using gene-wide association 
statistics we implicate an additional set of 22 novel associations that map onto a single gene. 
We show for the first time that the common variant association signal is highly enriched 
among genes that are intolerant to loss of function mutations and that variants in these genes 
persist in the population despite the low fecundity associated with the disorder through the 
process of background selection. Associations point to novel areas of biology (e.g. 
metabotropic GABA-B signalling and acetyl cholinesterase), reinforce those implicated in 
earlier GWAS studies (e.g. calcium channel function), converge with earlier rare variants 
studies (e.g. NRXN1, GABAergic signalling), identify novel overlaps with autism (e.g. 
RBFOX1, FOXP1, FOXG1), and support early controversial candidate gene hypotheses (e.g. 
ERBB4 implicating neuregulin signalling). We also demonstrate the involvement of six 
independent central nervous system functional gene sets in schizophrenia pathophysiology. 
These findings provide novel insights into the biology and genetic architecture of 
schizophrenia, highlight the importance of mutation intolerant genes and suggest a 
mechanism by which common risk variants are maintained in the population.   
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Schizophrenia is characterised by psychosis and negative symptoms such as social and 
emotional withdrawal. While onset of psychosis typically does not occur until late 
adolescence or early adult life, there is strong evidence from clinical and epidemiological 
studies that schizophrenia reflects a disturbance of neurodevelopment
1
.  It confers substantial 
mortality and morbidity, with a mean reduction in life expectancy of 15-30 years
2,3
. Although 
recovery is possible, most patients have poor social and functional outcomes
4
. No substantial 
improvements in outcomes have emerged since the advent of antipsychotic medication in the 
mid-20th century, a fact that has been attributed to a lack of knowledge of pathophysiology
1
.  
Schizophrenia is both highly heritable and polygenic, with risk ascribed to variants spanning 
the full spectrum of population frequencies
5-7
. The relative contributions of alleles of various 
frequencies is not fully resolved, but recent studies estimate that common alleles, captured by 
genome-wide association study (GWAS) arrays, capture between a third and a half of the 
genetic variance in liability
8
. There has been a long-standing debate, from an evolutionary 
standpoint, as to how common risk alleles might be maintained in the population, particularly 
given the early mortality and decreased fecundity associated with schizophrenia
9
. Various 
hypotheses have been proposed including compensatory advantage (balancing selection), 
whereby schizophrenia alleles confer reproductive advantages in particular contexts
10,11
; 
hitchhiking, whereby risk alleles are maintained by their linkage to positively selected 
alleles
12
; or contrasting theories that attribute these effects to rare variants and gene-
environment interaction
13
. Addressing these competing hypotheses is now tractable given 
advances from recent studies of common genetic variation in schizophrenia.  
The largest published schizophrenia GWAS, that from the Schizophrenia Working Group of 
the Psychiatric Genomics Consortium (PGC), identified 108 genome-wide significant loci 
and unequivocally demonstrated the value of increasing sample sizes for discovery in 
schizophrenia GWAS
5
. Here, we report by far the largest ancestrally and phenotypically 
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homogeneous GWAS study of schizophrenia to date (N=11 260 cases, 24,542 controls). We 
combine these new data with the previous published GWAS to identify novel facets of 
genetic architecture and biology, and demonstrate that the evolutionary process of 
background selection can contribute to the maintenance of risk alleles in the population. 
 
RESULTS 
GWAS and Meta-analysis 
We obtained genome-wide genotype information for the largest single-country study of 
schizophrenia (CLOZUK) based on 15,000 cases from the UK, 96% of whom were taking 
clozapine, an antipsychotic for treatment-resistant schizophrenia. Control datasets with UK 
ancestry were obtained from public repositories or through collaboration. To maximise 
homogeneity beyond that conferred by our ascertainment strategy, we set stringent thresholds 
for inclusion based on genotype-derived ancestry, resulting in a final CLOZUK GWAS of 
11,260 cases and 24,542 controls (5,220 cases and 18,823 controls not in previous 
schizophrenia GWAS - Methods; Figure S1; Figure S2). 
The CLOZUK GWAS analysis (λGC=1.281, λ1000=1.018) yielded 18 genome-wide significant 
(GWS=p<5x10
-8
) independent loci, four of which are novel (Extended Data Table 1; 
Figure S3; Figure S4). The CLOZUK SNP-based heritability (h
2
SNP) on the liability scale 
was 0.29 (assuming 1% prevalence; see Extended Data Table 2 for a range of plausible 
prevalences) using linkage-disequilibrium score regression (LDSR)
14
. We demonstrate 
common genetic architecture between the CLOZUK and the independent PGC sample 
(excluding all CLOZUK samples) by showing high genetic correlation (95%), sign test 
enrichment (99% of PGC GWS SNPs show the same direction of effect in CLOZUK: 
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p=2.04x10
-21
) and strong polygenic risk score overlap (p<1x10
-300
) – see Methods and 
Extended Data Table 3 and 4. 
Having demonstrated high genetic correlation between datasets, we performed meta-analysis 
of the CLOZUK and the independent PGC dataset, excluding related and overlapping 
samples (total 40,675 cases and 64,643 controls, λGC=1.586, λ1000=1.012; Figure S5). We 
identified 177 independently associated SNPs (Extended Data Table 5) that map to 143 
independent loci (Figure 1, Extended Data Table 6, Methods). Overall, the association 
signal at the majority of previously identified loci strengthened in the meta-analysis (Figure 
S6), although 14 of the PGC loci were no longer genome-wide significant (Extended Data 
Table 7). Of the 52 loci not identified by the PGC, two have been reported as genome-wide 
significant in other studies: ZEB2
15
 and a locus on chromosome 8 (38.0-38.3 MB)
16
. Thus we 
identify 50 novel genetic loci for schizophrenia (Extended Data Tables 6 and 8).  
 
Gene-based analysis 
To exploit the additional information provided by multiple sub-genome-wide significant SNP 
associations within single genes, we undertook gene-wide analyses using MAGMA
17
 
(Methods). In the full meta-analytic dataset, excluding the extended Major 
Histocompatibility region (xMHC) due to its complex LD structure, we identified 535 
genome-wide significant genes (p<2.5x10
-6
), 240 of which did not co-localize with a 
genome-wide significant SNP locus from either the present meta-analysis or the PGC study
5
 
(Extended Data Table 9). We then used the full genome-wide gene-based results to (i) 
investigate genetic architecture (ii) highlight single gene loci and (iii) conduct hypothesis and 
data-driven systems genomic analyses in schizophrenia. 
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Mutation intolerant genes  
Recent studies have shown that mutation intolerant genes capture much of the rare variant 
architecture of neurodevelopmental disorders such as autism, intellectual disability and 
developmental delay
18-20
. Work in parallel to the present study has shown that this extends to 
rare variants in schizophrenia (Singh et al, submitted). To investigate whether this holds for 
common variation, we analysed the set of loss-of-function (LoF) intolerant genes as defined 
by the Exome Aggregation Consortium (ExAC)
21
, using their preferred gene-level constraint 
metric, pLI ≥ 0.9 (probability of being LoF intolerant). Using gene set analysis in MAGMA, 
we found LoF intolerant genes (N=3230) were highly significantly enriched for 
schizophrenia common variant associations in comparison with all other genes (p=4.1x10
-16
).  
To quantify the contribution of SNPs within LoF intolerant genes to schizophrenia SNP-
based heritability (h
2
SNP) we conducted heritability analyses using partitioned LDSR
22
 
(Extended Data Table 10). Overall, genic SNPs account for 64% of h
2
SNP, a 1.23-fold 
enrichment (compared to that expected from SNP content) whereas non-genic SNPs were 
depleted for SNP heritability content (h
2
SNP=33%; enrichment=0.69). Consistent with the 
analysis using MAGMA, h
2
SNP was highly significantly enriched in LoF intolerant genes 
(2.01-fold; p=2.78x10
-24
). Common variation in LoF intolerant genes explained 30% of all 
h
2
SNP (equating to 47% of all genic h
2
SNP) despite containing only 15% of all SNP content 
(29% of the total genic SNP content).  In contrast, genes classed as non-LoF intolerant 
(pLI<0.9) were significantly depleted for h
2
SNP relative to their SNP content (0.90-fold; 
p=5.86x10
-3
), although in absolute terms, SNPs in these genes accounted for 34% of h
2
SNP. A 
finer scale analysis of the relationship between LoF intolerance scores and enrichment for 
association showed that enrichment is restricted to genes with a pLI score above 0.9 (Figure 
S7).  
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Common risk alleles maintained by background selection 
Our novel finding that LoF intolerant genes, which by definition are under strong selective 
pressure, are enriched for common schizophrenia risk variants raises the question of how 
such alleles are maintained in the population. While the contribution of ultra rare variation in 
mutation intolerant genes to disorders associated with low fecundity can be accounted for by 
de novo mutation
23,24
, this cannot explain the persistence of common alleles. To address this 
question, we used partitioned LDSR to test the relationship between schizophrenia associated 
alleles and SNP-based signatures of natural selection. These included measures of positive 
selection, background selection, and Neanderthal introgression. We examined the heritability 
of SNPs after thresholding them at extreme values for these metrics (top 2%, 1% and 0.5%), 
while adjusting for baseline annotation sets including LoF intolerant genes (Methods).  
We observed strong evidence for schizophrenia h
2
SNP enrichment in SNPs under background 
selection (BGS), which was consistent across all the thresholds we examined (Table 1). We 
also found a significant and consistent depletion of h
2
SNP in SNPs subject to positive selection 
as indexed by the CLR statistic. These two results are mutually consistent, as the calculation 
of the CLR statistic explicitly controls for B-statistic values
25
. This suggests that SNPs under 
positive selection, but under weak or no BGS, are depleted for association with 
schizophrenia. No significant relationship between h
2
SNP and other positive selection or 
Neanderthal introgression measures was found after correction for multiple testing (Table 1).  
To explicitly test the association of SNPs under background selection in LoF intolerant genes, 
we binned the B-statistic into four categories of increasing score, assigned SNPs in these bins 
to a LoF intolerant set, an “all other” genes set or a non-genic set (Figure S8). The lower 
boundary of the top bin (B-statistic >0.75) corresponds approximately to the top 2% BGS 
threshold in Table 1 and is equivalent to a reduction in effective population size estimated at 
each SNP of 75% or more
26
. We found significant heritability enrichment across all B-
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statistic intervals in LoF intolerant genes which increased progressively with higher B-
statistic scores. We also found enrichment for SNPs under BGS pressure in genes that are not 
LoF intolerant, although this was restricted to the highest B-statistic bin. There was no 
notable enrichment in any B-statistic intervals for non-genic regions. 
 
Notable single gene associations 
In considering the novel GWAS loci and gene-based results from the meta-analysis we 
highlight the subset of the findings most likely pointing to single genes, given the difficulties 
in accurately locating causal genes for complex disorders in a GWAS framework
27
. These 
single gene associations were defined as GWAS SNP loci that span only a single gene +/- 
20kb (N=22, 44% of novel loci, Extended Data Table 6) or MAGMA associated genes that 
were at least 100kb from any other genome-wide significant gene (N=76, Extended Data 
Table 9). We acknowledge this does not imply that these are inevitably the pathogenic genes 
but their likelihood of being so is higher than that for genes in multigenic loci.  
Details of the findings we consider most noteworthy are provided in Table 2. These results 
provide novel potential insights into schizophrenia pathogenesis as well as supporting 
existing hypotheses.  To our knowledge we provide the first genome-wide significant 
findings supporting GABA involvement in schizophrenia pathogenesis through both SNP-
based GWAS (GABBR2) and gene-based analysis (SLC6A11). Previous association studies 
have implicated calcium and cholinergic signalling involvement in schizophrenia
5,8
; we 
extend these findings by demonstrating association with an L-type calcium channel gene 
(CACNA1D) and with the acetyl cholinesterase gene (ACHE), a novel potential therapeutic 
target in schizophrenia which has also recently been implicated in autism through de novo 
mutation analysis
28
. We provide the first common variant support for NRXN1, previously 
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implicated by single-gene copy number variation (CNV) in schizophrenia, autism and 
intellectual disability
28,29
 and we also highlight the involvement of other genes that increase 
risk across neurodevelopmental disorders including RBFOX1. Finally we find evidence for 
association for two genes whose functions are intimately linked to two of the most prominent 
genes from schizophrenia candidate gene era, PDE4B, a DISC1 interactor
30
, and ERBB4 a 
binding partner of neuregulin1 (NRG1)
31
.   
 
Systems genomics  
We undertook gene set analysis in MAGMA to gain insights into the biological systems 
underpinning schizophrenia. To maximise power we restricted our primary analysis to 134 
gene sets we have previously postulated to be of likely relevance to the disorder on the basis 
of their involvement in the central nervous system, and which we subsequently showed 
effectively capture the excess CNV burden in schizophrenia
32
 (Extended Data Table 11). 
The set span subcellular neuronal function; neuronal cell physiology; cellular, brain region 
and fiber tract morphology; learning; behavior; and brain development, 
32
. In a GWAS 
context, we now show that collectively, this set captures a disproportionately high proportion 
of h
2
SNP (30% of total heritability; enrichment =1.63; 46% of genic heritability; Extended 
Data Table 10). 
Of the 134 sets, 54 were nominally significant of which 12 survived multiple-testing 
correction (family-wise error rate (FWER) p-value < 0.05, Extended Data Table 11). 
Stepwise conditional analysis, adjusting sequentially for the more strongly associated gene 
sets, resulted in six gene sets that were independently associated with schizophrenia (Table 3 
and Data Supplement).  These gene sets extend from low-level molecular and sub-cellular 
processes to broad behavioural phenotypes. The most strongly associated gene set is 
. CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/068593doi: bioRxiv preprint first posted online Aug. 9, 2016; 
11 
 
constituted by the targets of the Fragile X Mental Retardation Protein (FMRP)
33
. FMRP is a 
neuronal RNA-binding protein that interacts with polyribosomal mRNAs (the 842 target 
transcripts of this gene set
33
) and is thought to act by inhibiting translation of target mRNAs, 
including many transcripts of pre- and post-synaptic proteins. The FMRP target set has been 
shown to be enriched for rare mutational burden in de novo exome sequencing studies of 
autism
34
 and intellectual disability
35
. In schizophrenia studies, it has also been shown to be 
nominally significantly enriched for association signal in sequencing studies
8,35
 and in 
GWAS
5,8
 but only inconsistently in studies of copy number variation
32,36
. However, in none 
of these studies was enrichment at levels of significance that would be equivalent to genome 
wide significance (i.e. survive correction for a comprehensive testing of gene-sets in public 
databases). Thus we provide the most robust evidence to date for the involvement of this gene 
set in schizophrenia.  
We highlight another five gene sets that are independently associated with schizophrenia. 
Three of these derive from the Mouse Genome Informatics database
37
 and relate to 
behavioural and neurophysiological correlates of learning; Abnormal Behaviour 
(MP:0004924), Abnormal Nervous System Electrophysiology (MP:0002272) and Abnormal 
Long Term Potentiation (MP:0002207). We note that two of these gene sets (MP:0004924 
and MP:0002207) were among the five most enriched of 134 gene sets tested in a recent 
schizophrenia CNV analysis
32
. The remaining two independently associated genes sets were 
voltage-gated calcium channel complexes
38
 and  the 5-HT2C receptor complex
39
. The calcium 
channel finding confirms extensive evidence from common and rare variant studies 
implicating calcium channel genes in schizophrenia
5,8
, including a novel GWAS locus in 
CACNA1D identified in our meta-analysis. Whilst there is less convergent evidence in 
support of the involvement of the 5-HT2C receptor complex in schizophrenia, the fact that we 
identify independent association for this gene set implicates these genes in schizophrenia 
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pathophysiolology and potentially rejuvenates a previous avenue of 5-HT2C ligand 
therapeutic endeavour in schizophrenia research
40
.  However we interpret this result with 
caution given the small size of this gene set and the fact that a number of its genes encode 
synaptic proteins that are structurally related to other receptor complexes
39
, not only 5-HT2C.  
 
Systems genomics and mutation intolerant genes 
Together, LoF intolerant genes and the conditionally independent (“significant”) CNS-related 
gene sets together account for 39% of schizophrenia SNP-based heritability, equating to 61% 
of genic heritability (Figure 2A; Extended Data Table 10). This is likely to be an 
underestimation of the true effect of these gene sets since distal non-genic regulatory 
elements (not included in this analysis) will add to the heritability explained by these genes. 
In examining the relationship between the two gene sets (Figure 2A), genes belonging to 
both categories were the most highly enriched (2.6-fold; p=7.90x10
-15
), although LoF 
intolerant genes that were not annotated to our significant CNS gene sets still displayed 
robust enrichment for SNP-based heritability (1.74-fold; p=9.77x10
-10
), while genes that were 
in the significant CNS gene sets but had pLI<0.9 showed more modest enrichment (1.39-fold; 
p= 6.05x10
-4
). Notably genes outside these categories showed a depletion in heritability 
relative to their SNP content (enrichment=0.79, p=1.82x10
-7
). 
This general pattern remained when we focussed on the six significant CNS gene sets 
individually, in that the enrichment in these gene sets derives primarily from their intersection 
with LoF intolerant genes (Figure 2B). Indeed, only the targets of FMRP showed significant 
enrichment for SNPs in genes that are not LoF intolerant (2.06-fold; p=4.23x10
-5
).  
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Data-driven gene set analysis  
To set the systems genomics results in context, we undertook a purely data-driven analysis of 
a larger comprehensive annotation of gene sets from multiple public databases, totalling 
6,677 gene sets (Methods, Extended Data Table 12). The LoF intolerant gene set was the 
most strongly enriched followed by the two strongest associated functional gene sets we had 
specified in our CNS gene set analysis (FMRP targets and MGI Abnormal Behaviour genes). 
The other three gene sets that survive FWER correction and conditional analyses are calcium 
ion import (GO:0070509), membrane depolarisation during action potential (GO:0086010) 
and synaptic transmission (GO:0007268). These sets show a marked functional and genic 
overlap with the independently associated sets from our primary CNS systems genomic 
analysis. Indeed if we repeat the data-driven comprehensive gene set analysis whilst adjusting 
for the six independently associated CNS gene sets, then the only surviving enrichment term 
is the LoF intolerant genes. These results are consistent with those from CNV analysis
32
 in 
that they do not support annotations other than those related to CNS function, and 
demonstrate that hypothesis based analysis to maximise power does not substantially impact 
on the overall pattern of results. 
 
DISCUSSION 
In the largest genetic study of schizophrenia to date, we identify 50 novel genomic loci and a 
further 22 gene-wide associations that map onto to a single gene. We also explore the 
genomic architecture of, and the evolutionary pressures on, common variant associations to 
the disorder, and conduct extensive gene-based and systems genomic analyses. As discussed 
above and in table 1, novel findings point to GABAegic and cholinergic transmission as 
relevant to the aetiopathogenesis of schizophrenia.  We widen the array of calcium channel 
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receptors implicated in the disorder, and identify associations that support historical candidate 
gene networks that have been the subject of intensive functional investigation, but which 
have remained controversial in the absence of support from large scale genome-wide studies 
(PDE4B, ERBB4). We demonstrate congruence between common variant implicated genes 
and multiple rare variant associations to neurodevelopmental disorders, including NRXN1, 
RBFOX1, and FOXG1 indicating that studies of the impact of rare mutations in these genes 
are likely to be relevant to schizophrenia pathogenesis more widely. Systems genomic 
analysis highlights six gene sets that are independently associated with schizophrenia, and 
point to molecular, physiological and behavioural pathways involved in schizophrenia 
pathogenesis. We also provide the first support at a genome-wide significant equivalent level 
implicating targets of FMRP in the disorder.  
Our study provides the first evidence linking common variation in loss-of-function intolerant 
genes to risk of developing schizophrenia and demonstrates that these genes account for a 
substantial proportion (30%) of schizophrenia SNP-based heritability. Our findings underline 
the importance and value of well-curated catalogues of human genetic diversity and indicate 
that such resources have relevance for common variation and common disease. The Exome 
Aggregation Consortium
21
 reported that pLI score is positively correlated with gene 
expression across tissues, and this is also true for brain expression
41
. Furthermore high pLI 
genes have more protein-protein interaction partners, and pathways with the highest median 
pLI scores are ‘hub’ processes such as spliceosome and proteasome21. This evidence points to 
LoF intolerant genes being involved in core biological processes and presumably explains 
why they are under strong selective pressure. Given mutation intolerance and high selection 
pressure, our finding that common schizophrenia risk variants are enriched in loss-of-function 
intolerant genes appears paradoxical. However, we also present novel evidence that the major 
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mechanism responsible for the persistence of common schizophrenia variation, both in LoF 
intolerant genes and across the genome, is background selection (BGS). 
Selection against deleterious variants (purifying selection) is the main driver of genomic 
conservation over evolutionary timescales
42
. Regions of the genome under strong purifying 
selection constitute around 8% of the human genome
43
, and primarily include sequences 
which are important functionally and associated with fitness and survival
44
. BGS is a 
consequence of purifying selection occurring in regions of low recombination
45,46
. In such 
regions, selection against strongly deleterious variants causes whole haplotypes to be 
removed from the gene pool, which reduces genetic diversity at the locus in a manner 
equivalent to a reduction in effective population size
47
. This has the effect of impairing the 
efficiency of the selective process, allowing alleles with neutral or small deleterious effects 
that are not on haplotypes carrying strongly deleterious variants to rise in frequency by 
drift
45
. Our finding that schizophrenia-associated common SNPs are associated with high 
levels of BGS suggests a mechanism by which such variants, even if they are mildly 
deleterious, can be maintained in the population. The pruning of haplotypes carrying strongly 
deleterious mutations, which is expected to be particularly intense in LoF intolerant genes
21
, 
would allow these variants to persist in the population for as long as they reside on a 
haplotype free of these mutations. High LD additionally inhibits their amalgamation or 
replacement by recombination
45,48
. Such mechanisms of selection at linked sites have been 
shown to be compatible with the current knowledge about the genomic architecture of 
complex human traits
49
 and to influence phenotypes in model organisms, including gene 
expression
50
. 
We did not find enrichment for any measure of positive selection or Neanderthal 
introgression. A recent study explained a negative correlation between schizophrenia 
associations and metrics indicative of a Neanderthal selective sweep as evidence for positive 
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selection or polygenic adaptation in schizophrenia
12
. We do not replicate this correlation in 
our model, which addresses the contribution of BGS, and hence our results are not consistent 
with large contributions of positive selection to the genetic architecture of schizophrenia 
(Table 1). Indeed positive selection is not widespread in humans, as reported by other studies 
that explicitly considered or accounted for BGS
25,51
. Polygenic adaptation, the co-occurrence 
of many subtle allele frequency shifts at loci influencing complex traits
52
, though an 
intriguing possibility, has not been implicated in psychiatric phenotypes, including 
schizophrenia, in recent analyses
53,54
.  In contrast, BGS has been proposed as a mechanism 
driving Human-Neanderthal incompatibilities, as regions with higher estimated B-statistics 
have lower estimated Neanderthal introgression
55
. We therefore conclude that the bulk of the 
BGS signal we obtain is unlikely to be influenced by positive selection
26
 and that previous 
results linking positive selection and genetic variation in schizophrenia are likely to have 
been confounded by failure to control for BGS
46
. 
In summary, we demonstrate the capacity and continued importance of improving the power 
of genome-wide association studies for answering fundamental questions about the nature of 
schizophrenia. We identify large numbers of novel associations that both suggest novel, and 
support established, hypotheses about the biology of schizophrenia. We show convergence of 
risk variants on mutation intolerant genes, and identify background selection as the main 
mechanism by which common schizophrenia-related variation is maintained in the 
population.   
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METHODS 
Case sample collection 
We collected blood samples from those with treatment-resistant schizophrenia (TRS) in the 
UK through the mandatory clozapine blood-monitoring system for those taking clozapine, an 
antipsychotic licensed for TRS. Following national research ethics approval and in line with 
UK Human Tissue Act regulations we worked in partnership with the commercial companies 
that manufacture and monitor clozapine in the UK. We ascertained anonymous aliquots of the 
blood samples collected as part of the regular blood monitoring that takes place whilst taking 
clozapine due to a rare haematological adverse effect, agranulocytosis. The CLOZUK1 
sample was assembled in collaboration with Novartis (Basel, Switzerland). The company, 
through their proprietary Clozaril® Patient Monitoring Service (CPMS), provided whole-
blood samples and anonymised phenotypic information for 6,882 individuals with TRS (5528 
cases post-QC), which were included in the in a recent schizophrenia GWAS by the PGC
5
. 
The CLOZUK2 sample, previously unreported, was assembled in collaboration with the other 
major company involved in the supply and monitoring of clozapine in the UK, Leyden Delta 
(Nijmegen, Netherlands). The company, through their proprietary Zaponex® Treatment 
Access System (ZTAS), provided whole-blood samples and anonymised phenotypic 
information for 7,417 of those taking clozapine (4973 cases post-QC). Both Clozaril® and 
Zaponex® are bioequivalent brands of clozapine licensed in the UK
56
.  
We restricted the CLOZUK1 and CLOZUK2 samples to those with a clinician reported 
diagnosis of treatment-resistant schizophrenia. The UK National Institute for Health and Care 
Excellence (NICE) advise prescription of clozapine is reserved for those with schizophrenia 
in whom two trials of antipsychotics have failed (including one second-generation 
antipsychotic)
57
 which mirrors the criteria for licensed use of clozapine. The sole alternative 
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licensed indication for clozapine in the UK is for the management of resistant psychosis in 
Parkinson’s disease (PD)58 and, although this is a rare indication, we excluded PD patients 
(n=8) from the case dataset. We also excluded those with off-license indications, which 
included those with alternative clinician diagnoses of bipolar affective disorder and 
personality disorders (n=56). Together with the clinical guidelines outlined, these exclusions 
ensure that CLOZUK1 and CLOZUK2 samples are from those patients that conform to a 
clinical description of TRS. We have reported the use of CLOZUK1 as a schizophrenia 
dataset in previous publications
5,7,59,60
 and have presented evidence to support the use of 
TRS-defined individuals as valid schizophrenia samples
32
, which we have updated and 
present in Supplementary Note 1, including validation of a clinician diagnosis of TRS 
against research diagnostic criteria for schizophrenia.  
In addition we also included in our analysis a more conventional cohort of UK-based patients 
with schizophrenia (CardiffCOGS). Recruitment was via secondary care, mainly outpatient, 
NHS mental health services in Wales and England. These patients were not exclusively 
taking clozapine at the time of their recruitment. All cases underwent a SCAN interview
61
 
and case note review followed by consensus research diagnostic procedures and were 
included if they had a DSM-IV schizophrenia or schizoaffective disorder-depressive type 
diagnosis, as previously reported
7
. The CardiffCOGS samples were recruited and genotyped 
in two waves: CardiffCOGS1 (512 cases, included in a previous GWAS
5
) and CardiffCOGS2 
(247 cases).  
Genotyping for these case samples was performed by the Broad Institute (Massachusetts, 
USA) for the CLOZUK1 sample and CardiffCOGS1 cases, using Illumina 
HumanOmniExpress-12 and OmniExpressExome-8 chips as described elsewhere
7
. The 
CardiffCOGS2 cases and the CLOZUK2 sample were genotyped by deCODE Genetics 
(Reykjavík, Iceland), using Illumina HumanOmniExpress-12 chips. 
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As all of these samples are intrinsically related and their recruitment and genotyping 
conforms to clinical and technical standards, thus we have combined them and used the term 
“CLOZUK” throughout this manuscript to describe the schizophrenia case dataset.  
 
Control sample collection 
Control samples were collected from publicly available sources (EGA) or through 
collaboration with the holders of the datasets. Individual datasets were curated using the same 
procedures as the case-only datasets. In order to maximize the numbers of individuals that 
could be effectively included in the GWAS without introducing confounders, these datasets 
were chosen on the basis of having recruited individuals with self-reported UK ancestry 
(either exclusively or primarily) and having been genotyped on Illumina chips. A 
summarized view of all the datasets included in the GWAS is provided in Supplementary 
Note 2, which includes further details of the control datasets. 
 
Genotype quality-control (QC) 
Given the many data sources used and the variety of genotyping chips available, a stringent 
quality control (allowing only 2% of missing SNP and individual data) was performed 
separately in each individual dataset, using PLINK v1.9
62
 and following standard 
procedures
63
. To facilitate merging and to avoid common sources of batch effects
64
, all SNPs 
in each dataset were also aligned to the plus strand of the human genome (build 37p13), 
removing strand-ambiguous markers in the process. As most control datasets lacked any 
markers in the X and Y chromosomes, or in the mitochondrial DNA, every SNP from these 
regions was discarded in the combined genotype data. The final merge of all case and control 
datasets left 203,436 overlapping autosomal SNPs. 
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All individuals were imputed simultaneously in the Cardiff University high-performance 
computing cluster RAVEN
65
, using the SHAPEIT/IMPUTE2 algorithms
66,67
. As reference 
panels, a combination of the 1000 Genomes phase 3 (1KGPp3) and UK10K datasets was 
used, as this has previously been shown to increase the accuracy of imputation for individuals 
of British ancestry, particularly for rare variants
68
.  
After imputation, a principal component analysis (PCA) of common variants (MAF higher 
than 5%) was carried out to obtain a general summary of the population structure of the 
sample, using the EIGENSOFT v6 toolset
69
. A plot of the first two PCs showed the existence 
of a large fraction of cases (~20%) with no overlapping controls (Figure S1, A). A 
comparison with the 1KGPp3 dataset, performed using PCA and ADMIXTURE
70
 estimates, 
showed that most of these cases were similar in genetic ancestry to non-European individuals, 
namely from the East Asian or West African superpopulations (Figure S1, B). In order to 
ameliorate population stratification in the association analysis
71
, all individuals not falling 
into an area delimited by the mean and 3 standard deviations of the two first principal 
components of the control samples were excluded from further analyses (Figure S1, C). By 
repeating PCA only on the selected individuals, no outliers could be detected in the first two 
principal components, and ADMIXTURE plots were homogenised as well (Figure S2).  
The CLOZUK sample was further pruned by removing all individuals with inbreeding 
coefficients (F) higher than 0.2, and leaving only a random member of each pair with a 
relatedness coefficient (?̂?) higher than 0.2. Furthermore, to ensure the independence of our 
analyses with previous GWAS conducted by the Schizophrenia Working Group of the PGC, 
relatedness coefficients of CLOZUK individuals were also calculated with all the individual 
datasets included in the latest PGC GWAS
5
 following approval by the Consortium. Detected 
genetic relatives (or duplicates) were excluded in CLOZUK in the same way as intra-
population relatives. After this imputation and curation process, 35,802 samples (11,260 
. CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/068593doi: bioRxiv preprint first posted online Aug. 9, 2016; 
21 
 
cases and 24,542 controls) with 9.65 million imputed markers (INFO>0.3 and MAF>0.001) 
remained in the CLOZUK dataset. 
 
GWAS and reporting of independently-associated regions 
The CLOZUK schizophrenia GWAS was performed using logistic regression with 
imputation probabilities (“dosages”) adjusted for 11 PCA covariates. These covariates were 
chosen as those nominally significant (p < 0.05) in a logistic regression for association with 
the phenotype
72
. To avoid overburdening the GWAS power by adding too many covariates to 
the regression model
73
, only the first twenty PCs were considered and tested for inclusion, as 
higher numbers of PCs only become useful for the analysis of populations that bear strong 
signatures of complex admixture
74
. The final set of covariates included the first five PCs (as 
recommended for most GWAS approaches
75
) and PCs 6, 9, 11, 12, 13 and 19. Quantile-
quantile (QQ) and Manhattan plots are shown in Figure S3 and S4. 
In order to identify independent signals among the regression results, signals were 
amalgamated into putative associated loci using the same two-step strategy and parameters as 
PGC (Extended Data Table 1). In this procedure, regular LD-clumping is performed (r
2
 = 
0.1, p < 1x10
-4
; window size <3 Mb) in order to obtain independent index-SNPs. Afterwards 
loci were defined for each index SNP as the genomic region which contains all other imputed 
SNPs within an r
2≥0.6. To avoid inflating the number of signals in gene-dense regions or in 
those with complex LD, all loci within 250kb of each other were annealed. 
 
Meta-analysis with PGC 
A total of 6,040 cases and 5,719 controls from CLOZUK were included in the recent PGC 
study
5
. We reanalysed the PGC data after excluding all these cases and controls, obtaining a 
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sample termed ‘INDEPENDENT PGC’ (29,415 cases and 40,101 controls). Adding the 
summary statistics from this independent sample to the CLOZUK GWAS results allowed for 
a combined analysis of 40,675 cases and 64,643 controls (without duplicates or related 
samples). This meta-analysis was performed using the fixed-effects procedure in METAL
76
 
with weights derived from standard errors. For consistency with the PGC analysis, additional 
filters (INFO>0.6 and MAF>0.01) were applied to the CLOZUK and INDEPENDENT PGC 
summary statistics, leaving 8 million markers in the final meta-analysis results. QQ and 
Manhattan plots are shown in Figure S5 and Figure 2. The same procedure as above was 
used in order to report independent loci from this analysis (Extended Data Table 5, 
Extended Data Table 6). As raw PGC genotypes were not available for the LD-clumping 
procedure, 1KGPp3 was used as a reference. 
 
Estimation and assessment of a polygenic signal 
Association signals caused by the vast polygenicity underlying complex traits can be hard to 
distinguish from confounders related to sample relatedness and population stratification. In 
order to effectively disentangle this issue, we used the software LD-Score v1.0 to analyse the 
summary statistics of the CLOZUK GWAS, and estimate the contribution of confounding 
biases to our results by LDSR
14
. An LD-reference was generated using 1KGPp3 using the 
standard parameters implemented in the software. In order to improve accuracy, indels were 
discarded and markers used in this procedure were restricted to those with INFO>0.9 and 
MAF>0.01, a total of 5.16 million SNPs. The resulting LD-score intercept was 1.085±0.010, 
which compared to a mean χ2 of 1.417 indicates a polygenic signal contribution of at least 
80%. This is in line with other well-powered GWAS studies of complex human traits
14
, 
including schizophrenia
5
. SNP-based heritability (h
2
SNP) in our datasets (CLOZUK, 
INDEPENDENT PGC and the CLOZUK+PGC meta-analysis) was also calculated in this 
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analysis, and transformed to a liability scale using a population prevalence of 1% (registry-
based lifetime prevalence
77
). For reference and compatibility with epidemiological studies of 
schizophrenia, prevalence estimates of 0.7% (lifetime morbid risk
78
) and 0.4% (point 
prevalence
78
) were used for additional liability-scale h
2
SNP calculations (Extended Data 
Table 2). 
We also used LD-Score to compare the genetic architecture of CLOZUK and 
INDEPENDENT PGC, by calculating the correlation of their summary statistics
79
. A genetic 
correlation coefficient of 0.9541±0.0297 was obtained, with a p-value of 6.63x10
-227
. There 
were 76 independent SNPs at a genome-wide significant (GWS) level in the 
INDEPENDENT PGC dataset after excluding the extended major histocompatibility complex 
region (xMHC). Using binomial sign tests based on clumped subsets of SNPs we found all 
but 1 (98.6%) of the 76 GWS SNPs from the INDEPENDENT PGC were associated with the 
same direction of effect in the CLOZUK sample, a result highly unlikely to reflect chance
80
 
(p=2.04x10
-21
, Extended Data Table 3). Even of those with an association p-value less than 
10
-4
 in the INDEPENDENT PGC sample, 82% showed enrichment in the CLOZUK cases 
(p=3.44x10
-113
), confirming very large numbers of true associations will be discovered 
amongst these SNPs with increased sample sizes. Additionally, the new sample introduced in 
this study (CLOZUK2) was compared by the same methods with the independent PGC 
dataset and showed results consistent with the full CLOZUK analysis, providing molecular 
validation of this sample as a schizophrenia sample (Extended Data Table 3). 
We went on to conduct polygenic risk score analysis. Polygenic scores for CLOZUK were 
generated from INDEPENDENT PGC as a training set, using the same parameters for risk 
profile score (RPS) analysis in PGC
5
, arriving at a high-confidence set of SNPs for RPS 
estimation by removing the xMHC region, indels, and applying INFO>0.9 and MAF>0.1 cut-
offs. Scores were generated from the imputation dosage data, using a range of p-value 
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thresholds for SNP inclusion
81
 (5x10
-8
, 1x10
-5
, 0.001, 0.05 and 0.5). In this way, we can 
assess the presence of a progressively increasing signal-to-noise ratio in relation to the 
number of markers included
82
. As in the PGC study, we find the best p-value threshold for 
discrimination to be 0.05 and report highly significant polygenic overlap between the 
INDEPENDENT PGC and CLOZUK samples (p<1x10
-300
, r
2
=0.12, Extended Data Table 
4), confirming the validity of combining the datasets. For comparison with other studies we 
also report polygenic variance on the liability scale
83
, which amounted to 5.7% for CLOZUK 
at the 0.05 p-value threshold (Extended Data Table 4). As in the PGC study the limited r
2
 
and AUC in this analysis restricts the current clinical utility of these scores in schizophrenia. 
 
Gene set analysis 
In order to assess the enrichment of sets of functionally related genes, we used MAGMA 
v1.03
84
 on the CLOZUK+PGC meta-analysis summary statistics, after excluding the xMHC 
region. First, gene-wide p-values were calculated by combining the p-values of all SNPs 
inside genes after accounting for linkage disequilibrium (LD) and outliers. This was 
performed allowing for a window of 35 kb upstream and 10 kb downstream of each gene in 
order to capture the signal of nearby SNPs that could fall in regulatory regions
85,86
. Next we 
calculated competitive gene set p-values on the gene-wide p-values after accounting for gene 
size, gene set density and LD between genes. For multiple testing correction in each gene set 
collection, a FWER
87
 was computed using 100,000 re-samplings.  
We performed sequential analyses using three approaches: 
1. Loss-of-function intolerant genes: We tested the enrichment of the loss-of-function (LoF) 
intolerant genes described by ExAC 
21
. This set comprises all genes defined in the ExAC 
database
88
 as having a probability of LoF-intolerance (pLI) statistic higher than 90%. While 
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these genes do not form part of cohesive biological processes or phenotypes, they have been 
previously found to be highly expressed across tissues and developmental stages
21
. Also, they 
are enriched for hub proteins
89
, which makes them interesting candidates for involvement in 
the “evolutionary canalisation” processes that have been proposed to lead to pleiotropic, 
complex disorders
90
. 
2. CNS-related genes: These gene sets were compiled in our recent study
32
, and include 134 
gene sets related to different to aspects of central nervous system function and development. 
These include, among others, gene sets which have been implicated in schizophrenia by at 
least two independent large-scale sequencing studies
8,35
: targets of the fragile-X mental 
retardation protein (FMRP
33
), constituents of the N-methyl-D-aspartate receptor (NMDAR
91
) 
and activity-regulated cytoskeleton-associated protein complexes (ARC
92,93
), as well as CNS 
and behavioural gene sets from the Mouse Genome Informatics database version 6 
(http://www.informatics.jax.org) 
37.  
3. Data-driven: The final systems genomic analysis was designed as an “agnostic” approach, 
and thus a large number of gene sets from different public sources was included, which 
summed to a total of 6,677 sets. Gene set sources were selected to encompass a 
comprehensive collection of biochemical pathways and gene regulatory interaction networks, 
not necessarily conceptually related to psychiatric disorders. Similar approaches have been 
successful elsewhere
86,94
. In building this analytic approach, the LoF intolerant gene set and 
all sets in the CNS-related collection were used. Additionally, 2,693 gene sets with direct 
experimental evidence and a size of 10-200 genes
86
 were extracted from the Gene Ontology 
(GO
95
) database release 01/02/2016; 1,787 gene sets were extracted from the 4
th
 ontology 
level of the Mouse Genome Informatics database version 6; 1,585 gene sets were extracted 
from REACTOME
96
 version 55; 290 gene sets were extracted from KEGG
97
 release 04/2015; 
and 187 gene sets were extracted from OMIM
98
 release 01/02/2016.  
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Detailed results of the analyses of the CNS-related and data-driven collection are given in 
Extended Data Table 11 and Extended Data Table 12. Reported numbers of genes in each 
gene set are those with available data in the meta-analysis. This may differ from the original 
gene set description as some genic regions (such as those in the X chromosome) had null or 
poor SNP coverage. The gene content of the CNS-related gene sets that survive conditional 
analysis (“significant”) is given in MAGMA format in the Data Supplement. 
 
Partitioned heritability analysis of gene sets 
It is known that the power of a gene set analysis is closely related to the total heritability of 
the phenotype and the specific heritability attributable to the tested gene set
99
. In order to 
assess the heritability explained by the genes carried forward after the main gene set analysis, 
LD-Score was again used to compute a partitioned heritability estimate of CLOZUK+PGC 
using the gene sets as SNP annotations. As in the MAGMA analysis, the xMHC region was 
excluded from the summary statistics. These were also trimmed to contain no indels, and only 
markers with INFO > 0.9 and MAF > 0.01, for a total of 4.64 million SNPs. As a recognised 
caveat of this procedure is that model misspecification can inflate the partitioned heritability 
estimates
22
, all gene sets were annotated twice: Once using their exact genomic coordinates 
(extracted from the NCBI RefSeq database
100
) and another with regulatory regions taken into 
account using the same upstream/downstream windows as in the MAGMA analyses. 
Additionally, all SNPs not directly covered by our gene sets of interest were explicitly 
included into other annotations (“non-genic”, “genic but not LoF-intolerant”) based on their 
genomic location. Finally, the “baseline” set of 53 annotations from Finucane et al. 201522, 
which recapitulates important molecular properties such as presence of enhancers or 
phylogenetic conservation, was also incorporated in the model. All of these annotations were 
then tested jointly for heritability enrichment. We note that using exact genic coordinates or 
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adding regulatory regions made little difference to the estimated enrichment of our gene sets, 
and thus throughout the manuscript we report the latter for consistency with the MAGMA 
gene set analysis (Figure 2; Extended Data Table 10).   
 
Natural selection analyses 
We aimed to explore the hypothesis that some form of natural selection is linked to the 
maintenance of common genetic risk in schizophrenia
101-103
. In order to do this, for all SNPs 
included in the CLOZUK+PGC meta-analysis summary statistics, we obtained four different 
genome-wide metrics of positive selection (iHS
104
, XP-EEH
105
,  CMS
106
 and CLR
25
), one of 
background selection (B-statistic
26
, post-processed by Huber et al. 2016
25
) and one of 
Neanderthal introgression (average posterior probability LA
107
). The use of different statistics 
is motivated by the fact that each of them is tailored to detect a particular selective process 
that acted on a particular timeframe (see Vitti et al. 2013
51
 for a review). For example, iHS 
and CMS are based on the inference of abnormally long haplotypes, and thus are better 
powered to detect recent selective sweeps that occurred during the last ~30,000 years
108
, such 
as those linked to lactose tolerance or pathogen response
106
. On the other hand, CLR 
incorporates information about the spatial pattern of genomic variability (the site frequency 
spectrum
109
), and corrects explicitly for evidences of background selection, thus being able to 
detect signals from 60,000 to 240,000 years ago
25
. The B-statistic uses phylogenetic 
information from other primates (chimpanzee, gorilla, orang-utan and rhesus macaque) in 
order to infer the reduction in allelic diversity that exists in humans as a consequence of 
purifying selection on linked sites over evolutionary timeframes
48
. As the effects of 
background selection on large genomic regions can mimic those of positive selection
46
, it is 
possible that the B-statistic might amalgamate both, though the rather large diversity 
reduction that it infers for the human genome as a whole suggests any bias due to positive 
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selection is likely to be minor
44
. Finally, XP-EEH is a haplotype-based statistic which 
compares two population samples, and thus its power is increased for alleles that have 
suffered differential selective pressures since those populations diverged
105
. Though 
methodologically different, LA has a similar rationale by comparing human and Neanderthal 
genomes
107
, in order to infer the probability of each human haplotype to have been the result 
of an admixture event with Neanderthals. 
For this work, CLR, CMS, B-statistic and LA were retrieved directly from their published 
references, and lifted over to GRC37 genomic coordinates if required using the ENSEMBL 
LiftOver tool
110,111
. As the available genome-wide measures of iHS and XP-EEH were based 
on HapMap3 data
112
, both statistics were re-calculated with the HAPBIN
113
 software directly 
on the EUR superpopulation of the 1KGPp3 dataset, with the AFR superpopulation used as 
the second population for XP-EEH. Taking advantage of the fine-scale genomic resolution of 
these statistics (between 1-10 kb), all SNP positions present in CLOZUK+PGC were 
assigned a value for each measure, either directly (if the position existed in the lifted-over 
data) or by linear interpolation. To simplify the interpretation of our results, all measures 
were transformed before further analyses to a common scale, in which larger values indicate 
stronger effect of selection or increased probability of introgression. 
Heritability enrichment of these statistics was tested by the LD-Score partitioned heritability 
procedure. We derived binary annotations from the natural selection metrics by 
dichotomising at extreme cut-offs defined by the top 2%, 1% and 0.5% of the values of each 
metric in the full set of SNPs. This approach is widely used in evolutionary genomics, due to 
the difficulty of setting specific thresholds to define regions under selection
25,51
. Consistent 
with the previously described LDSR partitioned heritability protocol, enrichment was 
estimated for all binary annotations after controlling for 3 main categories of our set-based 
analysis (“non-genic”, “genic” and “genic LoF-intolerant”) and the 53 “baseline” categories 
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of Finucane et al. 2015
22
. We note that the LD-Score software allows use of an extension of 
the partitioned heritability framework to test the metrics as fully quantitative annotations. 
Results of this analysis replicated those reported here (data not shown), though it did not 
constitute our main approach as methodological details on this feature of LDSR are yet to be 
published. 
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Top 2% of scores  
(genome-wide) 
Top 1% of scores  
(genome-wide) 
Top 0.5% of scores  
(genome-wide) 
Metric Ref. Enrichment 
2-sided 
p-value 
Enrichment 
2-sided 
p-value 
Enrichment 
2-sided 
p-value 
Background Selection (B-statistic)  26 2.0612 0.0008 2.6477 1.2721x10-4 2.8073 1.0226x10-4 
Positive selection (CLR)  25 0.6069 0.0506 0.3154 1.1349x10-5 0.2382 1.1120x10-4 
Positive selection (CMS)  106 0.1703 0.0036 0.1902 0.0489 -0.0108 0.0736 
Positive selection (XP-EEH)  105 0.9918 0.9824 0.6211 0.4882 -0.0018 0.1666 
Positive selection (iHS)  104 0.8593 0.7095 0.7649 0.6992 1.3686 0.7130 
Neanderthal posterior probability (LA)  107 0.7465 0.2175 0.7895 0.4930 0.9067 0.8428 
 
Table 1. Heritability analysis of natural selection metrics.  
Partitioned LDSR regression results for SNPs thresholded by extreme values (defined as top percentiles vs all other SNPs) of each natural 
selection metric. All tests have been adjusted for 56 "baseline" annotations, which include categories such as “LoF-intolerant” and “conserved” 
(see Methods). Negative enrichments should be considered zero (no contribution to h
2
SNP by these SNPs). Underlined values indicate results 
surviving correction after adjusting for all tests (Bonferroni α= 0.05/18= 0.0028). Reference numbers for each metric indicate references in the 
main text. 
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Table 2. Genes with pre-existing genetic and functional hypotheses in schizophrenia or related neurodevelopmental disorders. Additional details 
an Extended Data Table 6 and Extended Data Table 9. 
Genes implicated by ‘single gene’ GWAS locus (locus overlaps with only one gene boundary (+/- 20kb)) 
Gene OR P value Comment 
GABBR2 0.92 1.02x10
-9
 
Encodes GABA-B receptor 2, a metabotropic G-protein coupled receptor. This is the first direct association of a GABA 
receptor gene in schizophrenia GWAS. Ionotropic GABA-A receptor complexes have recently been implicated at a pathway 
level in a schizophrenia CNV study
32
 
PDE4B 0.95 3.35x10
-8
 
An enzyme involved in cAMP signalling and an interactor of DISC1. Translocations of both genes have been implicated in 
multiple psychiatric disorders
30,114
. 
CACNA1D 1.07 1.38x10
-8
 
A voltage gated, L-type calcium channel sub-unit that is implicated in dopamine neuron pathology in Parkinson’s disease115 . 
There are four L-type alpha sub-units and this is the second to be associated with schizophrenia. The other, CACNA1C, is an 
established candidate gene (p=5.6x10
-20
 in this meta-analysis). 
RBFOX1 0.92 1.44x10
-8
 
Encodes FOX1, a neuronal RNA binding protein and splicing factor implicated in autism and neurodevelopment
116
. A number 
of additional novel loci highlight genes involved in transcription including FOXP1 and FOXG1, both of which have also been 
implicated in autism spectrum disorders and in regulating GABAergic/glutamatergic signalling
117-119
. In addition ASCL1 (a 
single gene locus in both GWAS and gene-wide analysis is a novel transcription factor gene which is involved in neuronal cell 
differentiation
120
. 
Genes implicated by gene-based analysis (no other genome-wide significant gene within 100kb) 
Gene P Value Comment 
ACHE 1.8x10
-6
 
Encodes acetyl cholinesterase (AChE) which hydrolyzes and inactivates the neurotransmitter acetylcholine. AChE inhibitors 
are used to treat cognitive impairment in dementia and have shown limited symptomatic benefits as adjunctive agents in 
schizophrenia trials
121,122
. Recently identified as enriched for de novo mutations in ASD
28
. We also implicate other cholinergic 
genes in the gene-based analysis: CHRNA3/CHRNA5/CHRNB4 (p values <7.6x10
-7
), CHRM4 (p=1.7x10
-12
); as well as GWAS 
analyses: CHRNA2 (p= 7.6x10
-12
) and CHRM3 (p=4.7x10
-10
). 
NRXN1 6.6x10
-7
 
The first genome-wide significant common variant finding for this gene. NRXN1 has been robustly implicated in schizophrenia 
pathogenesis by single-gene copy number variation analysis
29
. 
ERBB4 1.3x10
-7
 
A member of the tyrosine kinase receptor family that binds and is activated by the schizophrenia candidate gene neuregulin1 
(NRG1)
123
. 
SLC6A11 1.3x10
-6
 
Encodes a sodium-dependent GABA transporter, providing further support GABA involvement in schizophrenia pathogenesis.  
Another implicated gene, CLCN3, encodes a voltage-gated chloride channel involved in transmitter loading of GABAergic 
synapse vesicles.  SLC6A11 is one of two major GABA transporters in the brain, rare variants in which have been implicated 
in epilepsy, ID, and stereotypic behaviour
124,125
. 
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Gene Set 
Number of 
genes 
Enrichment 
p value (FWER) 
Conditional 
p value 
Targets of FMRP
33
 798 1x10
-5
 1.9x10
-8
 
Abnormal Behaviour 
(MP:0004924) 
1939 1.8x10
-4
 1.4x10
-5
 
5-HT2C receptor complex
39
 16 0.029 0.001 
Abnormal Nervous System 
Electrophysiology 
(MP:0002272) 
201 0.003 0.002 
Voltage-gated calcium 
channel complexes
38
 
196 0.011 0.016 
Abnormal Long Term 
Potentiation (MP:0002207) 
142 0.030 0.031 
    
Table 3. Functional gene set analysis highlights six independent gene sets associated 
with schizophrenia 
 
FMRP: Fragile X Mental Retardation Protein. 
MP refers to Mammalian Phenotype Ontology term of the MGI: Mouse Genome Informatics 
(http://www.informatics.jax.org)
37
, from which gene sets were derived. 
FWER: Westfall-Young family-wise error rate, as implemented in MAGMA
17,87
. 
Conditional p value refers to stepwise conditional analysis that adjusts sequentially for 
‘stronger’ associated gene sets. 
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Figure 1. Manhattan plot of schizophrenia GWAS associations from the meta-analysis of CLOZUK and an independent PGC dataset 
(N=105,318; 40,675 cases and 64,643 controls).  
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Figure 2. Partitioned heritability analysis of gene sets in schizophrenia. A: Heritability of 
genomic partitions and the six conditionally independent (“significant”) gene sets (Table 3). 
Radius of each segment indicates the degree of enrichment, while the arc (angle of each slice) 
indicates the percentage of total SNP-based heritability explained. No relative enrichment or 
depletion (enrichment=1) is shown by the dashed red line. B: Heritability of the significant 
CNS gene sets dissected by their overlap with LoF-intolerant genes. Asterisks indicate the 
significance of each heritability enrichment (* <= 0.05; ** <= 0.01; *** <= 0.001).  
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